ArticleFrontiers in pharmacology2021

Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway.

Xue Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.